Key points are not available for this paper at this time.
exchangers. At present, none of the inhibitors targeting acidic TMEs have been approved for clinical use in cancer treatment, except for proton pump inhibitors that target V-ATPase. Development of highly specific agents and the discovery of more sensitive and precise biomarkers may help improve the effectiveness of these inhibitors for cancer therapy.
Zhuang et al. (Wed,) studied this question.